Using dendritic cells (DCs) electroporated with whole RNA isolated from blasts of a patient with acute myeloid leukemia (AML), we were able to generate leukemia-specific cytotoxic T lymphocytes (CTLs) capable of recognizing the leucemic cells. To identify T-cell epitopes mediating lysis of malignant cells, peptides were eluted from the patient's blasts and analyzed by mass spectrometry (LC/MS)-based peptide sequencing. Using this approach, an HLA-A24-binding peptide derived from Bax inhibitor-1 (BI-1), a regulator of apoptosis pathways, was identified as an epitope recognized by the generated CTLs. To further characterize this novel antigenic peptide, CTLs were induced using DCs electroporated with RNA coding for BI-1 or pulsed with the cognate peptide. These CTLs generated from healthy donors in vitro efficiently lysed the patient's blasts as well as other HLA-matched leukemic cells. In conclusion, we identified a BI-1 peptide as a novel immunogenic tumorassociated antigen (TAA) in AML. In vitro induction of BI-1-specific CTLs by RNA transfection or pulsing of DCs with the synthetically generated peptide was a feasible and highly effective method to generate leukemia-specific CTLs. As BI-1 is (over-) expressed in a broad variety of malignancies, it may represent an interesting novel TAA in the context of cancer vaccines.
Introduction
A prerequisite for the development of cancer vaccination strategies is the identification and characterization of relevant tumor-associated antigens (TAAs) capable of mediating tumor cell elimination. In such immunotherapeutic approaches, dendritic cells (DCs), which are the most potent antigenpresenting cells (APCs) with the unique ability to activate naïve T cells and to initiate and maintain primary immune responses, are pivotal. 1, 2 Several approaches to identify TAAs were applied in the past. The first human tumor antigens were characterized by expression cloning that uses T-cell clones to identify the cognate T-cell epitope. The field of tumor immunology was further pushed forward by the pioneering work of Rammensee and co-workers that identified the so-called 'HLA motives' that opened the possibility to predict possible antigenic peptides for certain HLA class I molecules. 3 The immunogenicity of these peptides was confirmed by their ability to elicit T-cell responses. Using this 'reverse immunology' approach most of the currently available TAAs were identified. 4 The serological analysis of recombinant cDNA expression libraries technology further contributed several important antigens such as the cancer testis antigens. 5, 6 More recently, another approach combining microarray analysis with mass spectrometry (MS) was introduced as a highly effective method to identify T-cell epitopes. 7 The objective of this study was to identify novel immunogenic TAAs in acute myeloid leukemia (AML). Therefore, to verify the immunogenicity of antigens expressed by leukemic cells, total RNA was purified from blasts of an AML patient and used for the transfection of DCs generated from healthy donors. These APCs were used for the in vitro induction of leukemia-reactive cytotoxic T lymphocytes (CTLs). In standard 51 Cr-release assays, the generated CTLs efficiently lysed the respective AML blasts as well as HLA-matched tumor cell lines.
In a second step, to determine TAAs recognized by these CTLs, major histocompatibility complex (MHC)-associated peptides were directly released from the AML blasts and analyzed by mass spectrometry (LC/MS)-based peptide sequencing. 8, 9 Using this approach, a novel HLA-A24-binding peptide (AYVHMVTHF) derived from Bax inhibitor-1 (BI-1) was identified.
The BI-1 gene expression initially was found to be highly abundant in the postpubertal testis of the rat and, therefore, named testicular-enhanced gene transcript, but transcripts are also detected in normal heart, brain, placenta, lung, liver, skeletal muscle, kidney, and pancreas. 10 BI-1 is a small membrane spanning protein located predominantly in the endoplasmic reticulum. Functional analysis of human cDNAs in yeast cells revealed that BI-1 can inhibit apoptosis induced by Bax, a proapoptotic Bcl-2 family member.
11 BI-1 gene expression is accentuated not only in tissues with low apoptotic activity, such as the epithelium of the developing lung, but also in several human malignant tumors, such as prostate carcinoma, breast carcinoma, and brain tumors. [12] [13] [14] [15] Grzmil et al. 16 were able to increase spontaneous apoptosis rates in prostate carcinoma cell lines by suppressing BI-1 expression using specific small-interfering RNA. Lee et al. 17 presented evidence that BI-1 regulates generation of reactive oxygen species in the context of endoplasmic reticulum stress and thus inhibits apoptotic cell death. Taken together, these data suggest that BI-1 (over-) expression represses or deregulates apoptotic pathways in tumor cells and, therefore, is critically involved in tumorigenesis.
Materials and methods

Tumor cell lines
Tumor cell lines used in the experiments were grown in RP10 medium (RPMI 1640 with GlutaMAX-I supplemented with 10% heat inactivated FCS and 100 IU/ml penicillin/streptomycin; Invitrogen, Karlsruhe, Germany) at 37 1C and 5% CO 2 . HLA-A24-expressing tumor cell line used THP-1 (AML, HLA-A2, -A24). The following HLA-A24 negative tumor cell lines were used as a control: HL-60 (AML, HLA-A1) and NB-4 (AML, HLA-A11). K-562 cells were used to exclude natural killer (NK)-cell activity.
Generation of DCs from adherent PBMC
Generation of DCs from peripheral blood monocytes was performed as described earlier. 18, 19 In brief, peripheral blood mononuclear cells (PBMC) were isolated by Ficoll/Biocoll (Biochrom AG, Berlin, Germany) density gradient centrifugation of heparinized blood obtained from buffy coat preparations of healthy donors from the blood bank of the University of Tü bingen. Cells were seeded (1 Â 10 8 cells/10 ml/flask) into 75 cm 2 cell culture flasks (BD Falcon, Heidelberg, Germany) in serum-free X-VIVO 20 medium (BioWhittaker, Walkersville, MD, USA). After 2 h of incubation at 37 1C and 5% CO 2 , nonadherent cells were removed. The adherent blood monocytes were cultured in RP10 medium supplemented with human recombinant granulocyte macrophage colony-stimulating factor (GM-CSF, 100 ng/ml; Leukine Liquid Sargramostim; Berlex Laboratories, Richmond, CA, USA) and interleukin-4 (IL4, 20 ng/ml; R&D Systems, Wiesbaden, Germany) for 7 days. The medium was replenished with cytokines every second day.
Total RNA isolation
Total RNA was isolated from tumor cell lysates using RNeasy Mini anion-exchange spin columns (Qiagen, Hilden, Germany) according to the protocol for isolation of total RNA from animal cells provided by the manufacturer. The quantity and purity of RNA were determined by UV spectrophotometry. RNA samples were routinely checked by formaldehyde/agarose gel electrophoresis for size and integrity and were stored at À80 1C in small aliquots.
RNA electroporation of DCs
Electroporation of DCs with RNA was done as described earlier. 20, 21 Briefly, immature DCs were harvested, washed twice with X-VIVO 20 medium, and 5 Â 10 5 cells were resuspended in a volume of 200 ml. Subsequently, the cell suspension was mixed with 1.25 mg of RNA (2.5 mg/10 6 cell) in a 4-mm cuvette and electroporated using a Pulse Generator EPI 2500 (Dr L. Fischer, Heidelberg, Germany). The physical variables included voltage of 360 V, capacitance of 1200 mF, and pulse length of 10 ms. After electroporation, cells were immediately transferred to 37 1C prewarmed RP10 medium and returned to the incubator.
Induction of antigen-specific CTL response using an HLA-A24-binding synthetic peptide
The HLA-A24-binding peptide derived from the BI-1 protein (AYVHMVTHF, amino acids 45-53) was synthesized in an automated peptide synthesizer EPS221 (Abimed, Langenfeld, Germany) after the F-moc/tBu strategy and analyzed by highpressure liquid chromatography (Varian Star, Zinsser Analytics, Mü nchen, Germany) and MALDI-TOF MS (Future, GSG, Bruchsal, Germany). 8, 9 For CTL induction, 5 Â 10 5 DCs were pulsed with 50 mg/ml of the synthetic BI-1 peptide for 2 h, washed, and incubated with 3 Â 10 6 autologous PBMC in RP10 medium. After 7 days of culture, cells were restimulated with 2,5 Â 10 6 autologous peptide-pulsed PBMC and human recombinant interleukin-2 (IL2, 2 ng/ml; R&D Systems, Wiesbaden, Germany) was added on days 1, 3, and 5. Restimulation was repeated at least twice. On day 5 after the last restimulation, the cytolytic activity of induced CTL was analyzed in a standard 51 Cr-release assay. All experiments were performed at least three times using peripheral blood from different donors.
Peptidetarget titration
BI-1-specific CTLs were generated as described above. For peptide titration, DCs were incubated with titrated amounts (50 mg/ml-0.5 ng/ml) of the BI-1 peptide. BI-1-specific CTLs were added to the target cells with a constant effector to target ratio of 10:1.
Induction of antigen-specific CTL response using DCs transfected with RNA For CTL induction, 5 Â 10 5 DCs were transfected with RNA using electroporation as described above. Besides total tumor RNA from a patient's AML blasts, expressing BI-1, we also used in vitro transcribed RNA of BI-1 (BI-1-in vitro transcript (IVT)). The electroporation was performed in direct advance of the CTL induction. The CTLs were induced and restimulated as described above and analyzed in a standard 51 Cr-release assay. The experiments were confirmed at least three times with different donors.
Standard
51 Cr-release assay (CTL assay)
The standard 51 Cr-release assays were performed as described earlier. 18 Immature DCs, pulsed with BI-1 peptide (50 mg/ml) or transfected with BI-1-IVT or total tumor RNA and tumor cell line THP-1, were used as targets. DCs pulsed with irrelevant peptide (protein phosphatase 1, regulatory subunit 3A (PP1G), KYPENFFLL, amino113-121, HLA-A24 binding) or transfected with enhanced green fluorescence protein (EGFP)-IVT served as negative controls. The targets were labeled with 51 Cr sodium chromate in RP10 medium for 1 h at 37 1C. Subsequently, the targets were washed and cells (10 4 ) were transferred to a well of a round-bottomed 96-well plate. Varying numbers of CTL (CTL:targets 30:1, 10:1, 3:1, 1:1, 0.3:1, 0.1:1) were added to give a final volume of 200 ml. Cells were incubated for 4 h at 37 1C. At the end of the assay, supernatants (50 ml/well) were harvested and counted in a b-plate counter (MicroBeta, Perkin Elmer Wallac, Freiburg, Germany). The percentage of specific lysis was calculated as 100 Â (experimental releasespontaneous release)/(maximal release -spontaneous release). Spontaneous and maximal releases were determined in the presence of either RP10 medium or 1% Triton X-100, respectively. Antigen specificity of tumor cell lysis was further assessed in cold target inhibition assays by analyzing the capacity of cold (unlabeled) peptide-pulsed DCs to block lysis of hot (labeled) targets at an inhibitor to target ratio of 20:1. Inhibition of HLA class I or class II molecules was achieved by incubating DCs for 1 h before the assay either with the monoclonal antibodies W6/32 (10 mg/ml) directed against HLA class I molecules or Tü 39 (10 mg/ml) directed against HLA class II molecules (kindly provided by S. Stevanoviae, Institute for Cell Biology, Department of Immunology, Tü bingen, Germany).
IFN-g enzyme-linked immunospot (ELISPOT) assay
BI-1-specific CTLs were generated in vitro using peptide-pulsed DCs as described above. These CTLs were incubated in 200 ml of RP10 medium at a concentration of 5 Â 10 4 cells/well in a 96-well plate coated with antihuman IFN-g antibody (mAb 1-D1K, 10 mg/ml; Mabtech, Nacka Strand, Sweden) together with autologous PBMNCs (5 Â 10 4 cells/well) pulsed for 1 h with the HLA-A24-binding peptides. Spots were detected after 40-44 h of incubation with a biotin-labeled antihuman IFN-g antibody (Mab 7-B6-1-Biotin, 2 mg/ml; Mabtech).
Isolation of CD19
þ or CD3 þ T lymphocytes from PBMCs Enrichment of T and B lymphocytes was performed using immunomagnetic CD3 or CD19 microbeads (MACS system, Miltenyi Biotec, Bergisch Gladbach, Germany) according to the manufacturer's instructions.
Generation of BI-1-and EGFP-IVTs
For generation of BI-1-IVT, the plasmid pcDNA3 HA BI-1 (generously provided by Hang Jun Chea, The Burnham Institute, La Jolla, California, USA) was used. 17 Before IVT, this plasmid was linearized by XhoI restriction enzyme digestion. IVT under control of the T7 promoter was carried out using the T7 mMESSAGE mMACHINE Kit (Ambion, Huntingdon, UK) according to the protocol provided by the manufacturer. The BI-1-IVT was subsequent 3 0 polyadenylated by using the Poly(A) Tailing Kit (Ambion) according to the protocol provided. EGFP-IVT was generated as described earlier. 22 Purification of IVTs was performed with RNeasy Mini anion-exchange spin columns (Qiagen) according to the RNA cleanup protocol provided by the manufacturer. Quantity and purity of IVTs were determined by UV spectrophotometry. The IVTs were routinely checked by formaldehyde/agarose gel electrophoresis for size and integrity and stored at À80 1C in small aliquots.
Results
Induction of CTLs by DCs electroporated with total RNA purified from AML blasts
To generate anti-leucemic CTL responses, total RNA was purified from blasts of an HLA-A24 þ AML patient and used for the transfection of DCs generated from HLA-matched healthy donors. These APCs were used for the in vitro induction of leukemia-reactive CTLs. In standard 51 Cr-release assays, the generated CTLs efficiently lysed the respective AML blasts (Pat. 1) as well as the HLA-matched (HLA-A24 þ ) tumor cell line THP-1 (Figure 1a) . In contrast, the in vitro induced CTLs did not recognize HLA-A24
À HL-60 tumor cells indicating that an HLA-A24-binding epitope substantially contributes to the lytic activity. Furthermore, K-562 cells were spared indicating that the cytotoxic activity was not NK-cell mediated (Figure 1a) .
The HLA class I restriction of the induced CTLs was further confirmed by the addition of monoclonal antibodies directed against HLA molecules. In these experiments, DCs, that were generated from PBMCs of an HLA-A24 þ donor and electroporated with the respective AML-RNA (Pat. 1), were used as targets. As shown in Figure 1b , the specific lysis of the target cells could be blocked using an antibody directed against HLA class I molecules indicating that the elicited T-cell responses were HLA class I restricted. Consequently, the antibody directed against HLA class II molecules did not inhibit the lysis of the tumor cells. In contrast, DCs transfected with total RNA purified from non-autologous PBMCs used as a control were spared (Figure 1b) . These results were confirmed using at least three different donors.
To determine the possible TAAs recognized by these CTLs, MHC-associated peptides were directly isolated from the LC/MS-based peptide sequencing. Using this approach, a novel HLA-A24-binding peptide (AYVHMVTHF) derived from BI-1 was identified.
In next experiments, CTLs were induced by total RNA derived from AML blasts (Pat. 1) as above. As target cells in 51 Cr-release assays, autologous HLA-A24 þ DCs loaded with the novel BI-1 peptide were included as target cells. Figure 2a shows that the induced CTLs did lyse cells loaded with BI-1 peptide, whereas DCs loaded with irrelevant HLA-A24 þ PP1G peptide were spared.
To further confirm our findings, we in addition included autologous HLA-A24
þ DCs transfected with an excess of pure BI-1-IVT as targets in the standard 51 Cr-release assays. As shown in Figure 2a , these cells were efficiently Iysed by the CTLs. In contrast, the in vitro induced T cells did not recognize DCs transfected with irrelevant EGFP-IVT. The specificity of the generated CTLs was further analyzed in cold target inhibition assays.
The THP-1 cell line did express the BI-1 gene as ascertained by real-time-polymerase chain reaction analysis (data not shown). Therefore, in cold target inhibition assays, DCs loaded with the HLA-A24-binding BI-1 peptide could efficiently inhibit the recognition of the HLA-matched BI-1-expressing (BI-1 þ ) tumor cell line THP-1, thus confirming that the in vitro-induced CTLs are specific for the respective BI-1 epitope. In contrast, DCs loaded with an irrelevant peptide (PP1G) could not inhibit the recognition of tumor cell-derived BI-1 epitopes. K-562 cells were spared, indicating that the cytotoxic activity was not NK-cell mediated (Figure 2b) .
These data showed that DCs electroporated with total RNA purified from AML blasts can induce specific class I restricted CTLs that recognize BI-1-expressing cells in an antigen-specific and HLA-restricted manner in vitro.
Induction of BI-1-specific CTLs using peptide-pulsed DCs
To analyze the presentation of BI-1-derived T-cell epitopes, we induced BI-1-specific CTLs in vitro using DCs derived from adherent PBMCs of HLA-A24 þ healthy donors. These DCs were pulsed with the novel HLA-A24-binding antigenic BI-1 peptide and used as APCs for generation of CTLs. The cytotoxicity of the in vitro induced CTLs was assessed in a standard 51 Cr-release assay. As shown in Figure 3a , the CTL line obtained after several weekly restimulations with autologous DCs loaded with the cognate peptide showed HLA-A24-peptide-specific killing: T cells only recognized DCs loaded with the respective BI-1-HLA-A24 þ peptide, whereas they did not lyse target cells pulsed with an irrelevant HLA-A24-binding peptide (PP1G), confirming the specificity of the cytolytic activity (Figure 3a and b) .
In further experiments, we included the AML blasts from patient 1 from which the BI-1 peptide was eluted as target cells in 51 Cr-release assays. As shown in Figure 3b , these cells were efficiently lysed by the CTLs induced by the cognate BI-1 peptide. These findings were confirmed by including the Characterization of BAX inhibitor-1 as a novel leukemia-associated antigen SM Schmidt et al
HLA-24
þ / BI-1 þ tumor cell line THP-1 that was efficiently recognized. In contrast, the HLA-24 À /BI-1 þ AML cell lines HL-60 or NB-4 were spared.
In next series of experiments using CTLs induced with the BI-1 peptide, we included DCs electroporated with total RNA from different BI-1 þ AML-patients (Pat. 1, Pat. 2) as target cells in the cytotoxicity assays. As indicated in Figure 3c , these cells were efficiently lysed, whereas DCs electroporated with BI-1
þ -or PBMC-RNA were spared. The BI-1 expression was detected by real-time-polymerase chain reaction (data not shown).
The sensitivity of the CTL-mediated lysis of target cells was analyzed by titration of the BI-1 peptide for the loading of DCs as target cells in 51 Cr-release assays. As shown in Figure 3d , specific lysis of 50% was achieved when loading DCs with approximately 5.0 mg/ml BI-1 peptide and recognizes targets up to 0.01 mg/ml.
These findings indicate that DCs loaded with BI-1-derived peptide can induce specific CTLs that recognize cells presenting BI-1 epitopes in an antigen-specific and HLA-A-restricted manner.
Induction of BI-1-specific CTLs using DCs electroporated with BI-1-IVT
In the next set of experiments, we sought to analyze the feasibility to induce BI-1-specific CTLs by DCs electroporated with an excess of pure full-length BI-1-IVT that coded for the entire BI-1 protein. Therefore, monocyte-derived DCs were generated from the PBMCs of healthy HLA-A24 þ donors and transfected with BI-1-IVT. DCs loaded with either the BI-1 peptide or transfected with the cognate BI-1-IVT were used as target cells. As ascertained in the standard 51 Cr-release assay, the induced CTLs did lyse cells loaded with BI-1 peptide, whereas DCs loaded with irrelevant HLA-24 þ PP1G peptide or electroporated with irrelevant EGFP-IVT were spared (Figure 4a) .
To further confirm and extend our findings, we used total RNA of various BI-1 þ patients (Pat. 1 (AML), 2 (AML), 4 (CML)) for the transfection of DCs and used them as targets. As shown in Figure 4b , these target cells were efficiently lysed by the CTLs. In contrast, the in vitro induced T cells did not recognize DCs electroporated with RNA purified from a BI-1 patient (Pat. 3) or with RNA derived from purified CD34 þ cells. We also included BI-1 þ /HLA-A24 À and BI-1 þ /HLA-A24 À tumor cell lines as target cells. As shown in Figure 4c , the CTLs generated as above did recognize the HLA24 þ /BI-1 þ cell line THP-1 as well as the patients 1 blast cells, but spared the HLA24 À cell line HL-60 as well as purified autologous B or T lymphocytes.
Furthermore, the specific lysis of the blast cells from which the BI-1 peptide was derived (Pat. 1) could be blocked using a monoclonal antibody directed against HLA class I molecules indicating that the elicited T-cell responses were HLA class I restricted. Consequently, the antibody directed against HLA class II molecules did not inhibit the lysis of the tumor cells (Figure 4d ).
These data indicate that DCs electroporated with an excess of pure full-length BI-1-IVT can result in the presentation of BI-1-derived peptides on the cell surface that can induce BI-1-specific CTLs that recognize BI-1 þ target cells in an antigen-specific manner in vitro.
For cold target inhibition experiments, unlabeled DCs loaded with HLA-A24-binding BI-1 peptide or with irrelevant HLA-A24-binding PP1G-derived peptide as a control were added to 51 Cr-labeled AML blasts (Pat. 1; Figure 5a ) or THP-1 cells (Figure 5b ). CTLs generated with DCs electroporated with pure BI-1-IVT were used as effector cells in these experiments. To further analyze and confirm the antigen specificity of the CTLs induced by DCs electroporated with BI-1-IVT, we performed IFN-g ELISPOT assays. For the stimulation of the CTLs, DCs loaded with the BI-1 peptide or an irrelevant HLA-A24-binding peptide (PP1G) was used. CTLs were induced by DCs electroporated with BI-1-IVT.
As shown in Figure 5c , DC loaded with the BI-1 peptide induced a significant increase of BI-1-specific CD8 þ T cells. In contrast, the CTLs showed significant lesser IFN-g secretion when incubated with DC loaded with an irrelevant HLA-A24-binding peptide.
Discussion
During the last decade, intensive research was performed to develop new immunotherapeutic approaches for the treatment of malignant diseases as an additional strategy to traditional treatments. A prerequisite is the understanding of the molecular pathways required for induction and maintenance of the immunosurveillance and immunoresponse and the development of methodologies to generate tumor-specific antigen and/ or TAA-specific CTLs as well as DCs as immunological therapeutic agents. This requires the availability of well defined and characterized tumor-specific antigens and/or TAAs as target structures. In past years, a large number of tumor-specific antigens and TAAs have been identified, which can be recognized by T cells. 23 However, it became clear that these antigens have to be 'relevant' as a means to have an important function in the development, function, or survival of a malignant cell. Another central aspect of designing antigen-specific vaccination strategies is to use a potent tool to overcome the obstacles of immunosuppression and immunological tolerance, such as DCs.
DCs possess the unique ability to activate naïve T cells and to initiate and maintain primary immune responses.
1,2,24 They originate from the bone marrow and their precursors' home through the blood stream to almost all organs, in which they can be found as sentinels in an immature state with high endocytic and phagocytic capacity. On contact with bacterial DNA, LPS, dsRNA, inflammatory cytokines such as TNF-a or IL-1, or interaction with activated T cells, the interstitial DCs change their phenotype and function and migrate to the germinal centers of regional lymph nodes in which they present antigens captured in the periphery to resting or naïve T cells and induce antigen-specific T-cell responses. The therapeutical concept to elicit a specific immune response against microorganisms, viruses, or cancer is to isolate or generate autologous DCs from the patients' blood, to manipulate them by peptide loading or RNA transfection in vitro, and to reinfuse them into the patient as a vaccine. [25] [26] [27] [28] [29] In the present work, using the mentioned approach of isolating of MHC-associated peptides directly from LC/MSbased peptide sequencing, we identified a novel HLA-A24-binding antigenic peptide derived from BI-1.
BI-1 is a small membrane spanning protein that can interact with antiapoptotic BCL2 and BCLxL and suppresses apoptosis induced by BAX, etoposide, staurosporine, and growth factor deprivation. 11 It was shown that BI-1 is expressed in tissues in which the rate of apoptotic cell death is high such as in the lung during late prenatal and early postnatal development. 13 Furthermore, BI-1 is highly expressed in tumor cells such as human prostate cancer, human breast cancer, human brain tumor, or large cell lymphoma. 12, [14] [15] [16] 30 In addition, in this work, we found BI-1 to be expressed in primary AML-blasts and -cell lines. Consistent with these findings, small-interfering RNAmediated inhibition of BI-1 expression in different prostate carcinoma cell lines led to caspase-3 activation and spontaneous apotosis. 16 Considered together, these data provide significant evidence that BI-1 is a cell death regulator critically involved in deregulation of apoptosis in tumor cells and participating in the tumorigenic process and tumor maintenance. The important role of this molecule in tumor biology turns it into an ideal target for immunotherapeutic approaches. Consequently, we analyzed the possible use of the novel BI-1 peptide as T-cell epitope that can induce antigen-specific CTLs and mediate AML cell lysis. To accomplish this, we used PBMCs from HLA-A24-positive donors in an in vitro immunization protocol. CTL induction was carried out using monocytederived DCs pulsed with the BI-1 peptide or transfected with in vitro transcribed BI-1-RNA as APCs. After several rounds of restimulations, cultures were tested for their lytic activity against target cells pulsed with the cognate peptide, AML blasts or human tumor cell lines expressing BI-1. The in vitro induced Figure 5 Induction of BI-1-specific CTLs using DCs electroporated with BI-1-IVT specifically recognize BI-1-derived epitopes. Immature monocyte-derived DCs generated from healthy donors (HLA-A24 þ ) were electroporated with pure BI-1-IVT and used as APCs for the induction of antigen-specific CTLs. The cytolytic activity of the generated CTLs was determined after several weekly restimulations in a standard peptide-specific CTLs were not only able to lyse target cells pulsed with the antigenic peptide, but also recognized tumor cells endogenously expressing the BI-1 protein in an antigenspecific and HLA-restricted manner.
To further analyze the specificity of the elicited CTL responses and presentation of identified peptide, we used DCs that were electroporated with an excess of pure full-length BI-1-IVT as target cells in standard 51 Cr-release assays. The in vitro generated CTLs efficiently lysed peptide-pulsed DCs and the DCs transfected with antigenic RNA, showing that the peptides used for CTL induction are also processed and presented on transfection of BI-1-IVT.
In conclusion, our study describes the identification of a novel broadly expressed T-cell epitope derived from the BI-1 protein that represents an interesting candidate to be applied in immunotherapies of human malignancies and extend the number of possible CTL epitopes that can be used for the design of cancer vaccines.
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